Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001
-
Shares outstanding
-
19,139,684
-
Total 13F shares
-
11,391,805
-
Share change
-
+239,937
-
Total reported value
-
$349,891,420
-
Price per share
-
$30.78
-
Number of holders
-
67
-
Value change
-
+$8,387,255
-
Number of buys
-
28
-
Number of sells
-
20
Institutional Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) as of Q4 2025
As of 31 Dec 2025,
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) was held by
67 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,391,805 shares.
The largest 10 holders included
ARCH Venture Management, LLC, GSK plc, MWG Caph Ltd, VANGUARD GROUP INC, Foresite Capital Management IV, LLC, Orland Properties Ltd, Almitas Capital LLC, Foresite Capital Management V, LLC, venBio Partners LLC, and CITADEL ADVISORS LLC.
This page lists
67
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.